Compounds for treatment of cancer
The present invention relates to novel compounds having anti-cancer activity, methods of making these compounds, and their use for treating cancer and drug-resistant tumors, e.g. melanoma, metastatic melanoma, drug resistant melanoma, prostate cancer and drug resistant prostate cancer.
1. A compound represented by the structure of formula XXIII:
wherein
R 1 , R 2 , and R 3 are independently hydrogen, O-alkyl, O-haloalkyl, F, Cl, Br, I, haloalkyl, CN, —CH 2 CN, hydroxyl, —(CH 2 ) i NHCH 3 , —(CH 2 ) i NH 2 , —(CH 2 ) i N(CH 3 ) 2 , —OC(O)CF 3 , C 1 -C 5 linear or branched alkyl, alkylamino, aminoalkyl, —OCH 2 Ph, —NHCO-alkyl, COOH, —C(O)Ph, C(O)O-alkyl, C(O)H, or —C(O)NH 2 , wherein (R 1 ) m , R 2 and R 3 collectively are not a single methyl group;
R 4 , R 5 and R 6 are independently hydrogen, O-alkyl, O-haloalkyl, F, Cl, Br, I, haloalkyl, CN, —CH 2 CN, NH 2 , hydroxyl, —(CH 2 ) i NHCH 3 , —(CH 2 ) i NH 2 , —(CH 2 ) i N(CH 3 ) 2 , —OC(O)CF 3 , C 1 -C 5 linear or branched alkyl, alkylamino, aminoalkyl, —OCH 2 Ph, —NHCO-alkyl, COOH, —C(O)Ph, C(O)O-alkyl, C(O)H, —C(O)NH 2 or NO 2 , wherein R 4 , R 5 , and R 6 cannot all be hydrogen;
R 9 is hydrogen, linear or branched, substituted or unsubstituted alkyl, substituted or unsubstituted cycloalkyl, —CH 2 Ph, substituted benzyl, haloalkyl, aminoalkyl, —OCH 2 Ph, substituted or unsubstituted SO 2 -aryl, substituted or unsubstituted —(C═O)-aryl or OH;
R 12 is linear unsubstituted alkyl, substituted or unsubstituted cycloalkyl, unsubstituted aryl, —CH 2 Ph, substituted benzyl, haloalkyl, aminoalkyl, —OCH 2 Ph, substituted or unsubstituted SO 2 -aryl, substituted or unsubstituted —(C═O)-aryl or OH;
wherein substitutions are independently selected from the group of hydroxyl, an aliphatic straight- or branched-chain C 1 to C 10 hydrocarbon, alkoxy, haloalkoxy, aryloxy, nitro, cyano, alkyl-CN, halo, haloalkyl, dihaloalkyl, trihaloalkyl, COOH, C(O)Ph, C(O)-alkyl, C(O)O-alkyl, C(O)H, C(O)NH 2 , —OC(O)CF 3 , —OCH 2 Ph, amino, aminoalkyl, alkylamino, mesylamino, dialkylamino, arylamino, amido, NHC(O)-alkyl, urea, alkyl-urea, alkylamido, haloalkylamido, arylamido, aryl, and C 5 to C 7 cycloalkyl, arylalkyl, and combinations thereof;
X is a bond or NH;
Y is —C═O;
i is an integer between 1-5;
n is an integer between 1-3; and
m is an integer between 1-3;
or its pharmaceutically acceptable salt, hydrate, polymorph, tautomer or stereoisomer.
2. The compound of claim 1 , wherein said compound is represented by the structure of formula XXIV:
R 1 , R 2 , and R 3 are independently hydrogen, O-alkyl, O-haloalkyl, F, Cl, Br, I, haloalkyl, CN, —CH 2 CN, hydroxyl, —(CH 2 ) i NHCH 3 , —(CH 2 ) i NH 2 , —(CH 2 ) i N(CH 3 ) 2 , —OC(O)CF 3 , C 1 -C 5 linear or branched alkyl, alkylamino, aminoalkyl, —OCH 2 Ph, —NHCO-alkyl, COOH, —C(O)Ph, C(O)O-alkyl, C(O)H, or —C(O)NH 2 , wherein R 1 , R 2 and R 3 are not two hydrogens and a methyl group;
R 4 , R 5 and R 6 are independently hydrogen, O-alkyl, O-haloalkyl, F, Cl, Br, I, haloalkyl, CN, —CH 2 CN, NH 2 , hydroxyl, —(CH 2 ) i NHCH 3 , —(CH 2 ) i NH 2 , —(CH 2 ) i N(CH 3 ) 2 , —OC(O)CF 3 , C 1 -C 5 linear or branched alkyl, alkylamino, aminoalkyl, —OCH 2 Ph, —NHCO-alkyl, COOH, —C(O)Ph, C(O)O-alkyl, C(O)H, —C(O)NH 2 or NO 2 , wherein R 4 , R 5 , and R 6 cannot all be hydrogen;
R 9 is hydrogen, linear or branched, substituted or unsubstituted alkyl, substituted or unsubstituted cycloalkyl, substituted or unsubstituted aryl, —CH 2 Ph, substituted benzyl, haloalkyl, aminoalkyl, —OCH 2 Ph, substituted or unsubstituted SO 2 -aryl, substituted or unsubstituted —(C═O)-aryl or OH;
R 12 is linear unsubstituted alkyl, substituted or unsubstituted cycloalkyl, —CH 2 Ph, substituted benzyl, haloalkyl, aminoalkyl, —OCH 2 Ph, substituted or unsubstituted SO 2 -aryl, substituted or unsubstituted —(C═O)-aryl or OH;
wherein substitutions are independently selected from the group of hydroxyl, an aliphatic straight- or branched-chain C 1 to C 10 hydrocarbon, alkoxy, haloalkoxy, aryloxy, nitro, cyano, alkyl-CN, halo, haloalkyl, dihaloalkyl, trihaloalkyl, COOH, C(O)Ph, C(O)-alkyl, C(O)O-alkyl, C(O)H, C(O)NH 2 , —OC(O)CF 3 , —OCH 2 Ph, amino, aminoalkyl, alkylamino, mesylamino, dialkylamino, arylamino, amido, NHC(O)-alkyl, urea, alkyl-urea, alkylamido, haloalkylamido, arylamido, aryl, and C 5 to C 7 cycloalkyl, arylalkyl, and combinations thereof;
Y is —C═O
i is an integer between 1-5;
n is an integer between 1-3; and
m is an integer between 1-3;
or its pharmaceutically acceptable salt, hydrate, polymorph, tautomer or stereoisomer.
3. A pharmaceutical composition comprising a compound according to claim 1 and a pharmaceutically acceptable carrier.
4. A method of treating, suppressing, reducing the severity, reducing the risk, or inhibiting cancer comprising administering a compound according to claim 1 to a subject having cancer under conditions effective to treat the cancer.
5. The method of claim 4 , wherein said cancer is selected from the group consisting of prostate cancer, breast cancer, ovarian cancer, skin cancer, melanoma, lung cancer, colon cancer, leukemia, renal cancer, CNS cancer, and combinations thereof.
6. The method of claim 5 , wherein said cancer is metastatic cancer.
7. The method of claim 5 , wherein said administering is carried out in combination with another cancer therapy.
8. A method of treating a drug resistant tumor or tumors comprising administering a compound according to claim 1 to a subject suffering from cancer under conditions effective to treat the drug resistant tumor or tumors.
9. The method of claim 8 , wherein said tumor is melanoma cancer tumor.
10. The method of claim 8 , wherein said tumor is metastatic melanoma tumor.
11. The method of claim 8 , wherein said tumor is prostate cancer tumor.
12. The method of claim 8 , wherein said tumor is ovarian cancer tumor.
13. The method according to 8 , wherein said administering is carried out in combination with another cancer therapy.
14. A method of destroying a cancerous cell comprising providing a compound according to claim 1 and contacting the cancerous cell with the compound under conditions effective to kill the cancer cell.
15. A compound represented by the structure of formula XXIII:
XXIII
wherein
R 1 , R 2 , R 3 , R 4 , R 5 and R 6 are independently hydrogen, O-alkyl, O-haloalkyl, F, Cl, Br, I, haloalkyl, CN, —CH 2 CN, NH 2 , —(CH 2 ) i NHCH 3 , —(CH 2 ) i NH 2 , —(CH 2 ) i N(CH 3 ) 2 , —OC(O)CF 3 , C 1 -C 5 linear or branched alkyl, alkylamino, aminoalkyl, —OCH 2 Ph, —NHCO-alkyl, COOH, —C(O)Ph, C(O)O-alkyl, C(O)H, —C(O)NH 2 or NO 2 , wherein R 4 , R 5 , and R 6 cannot all be hydrogen;
R 9 is hydrogen, linear or branched, substituted or unsubstituted alkyl, substituted or unsubstituted cycloalkyl, substituted or unsubstituted aryl, —CH 2 Ph, substituted benzyl, haloalkyl, aminoalkyl, —OCH 2 Ph, substituted or unsubstituted SO 2 -aryl, substituted or unsubstituted —(C═O)-aryl or OH;
R 12 is linear unsubstituted alkyl, substituted or unsubstituted cycloalkyl, —CH 2 Ph, substituted benzyl, haloalkyl, aminoalkyl, —OCH 2 Ph, substituted or unsubstituted SO 2 -aryl, substituted or unsubstituted —(C═O)-aryl or OH;
wherein substitutions are independently selected from the group of hydroxyl, an aliphatic straight- or branched-chain C 1 to C 10 hydrocarbon, alkoxy, haloalkoxy, aryloxy, nitro, cyano, alkyl-CN, halo, haloalkyl, dihaloalkyl, trihaloalkyl, COOH, C(O)Ph, C(O)-alkyl, C(O)O-alkyl, C(O)H, C(O)NH 2 , —OC(O)CF 3 , —OCH 2 Ph, amino, aminoalkyl, alkylamino, mesylamino, dialkylamino, arylamino, amido, NHC(O)-alkyl, urea, alkyl-urea, alkylamido, haloalkylamido, arylamido, aryl, and C 5 to C 7 cycloalkyl, arylalkyl, and combinations thereof;
X is a bond, or NH;
Y is —C═O;
i is an integer between 0-5;
n is an integer between 1-3; and
m is an integer between 1-3;
or its pharmaceutically acceptable salt.
16. A compound represented by the structure of formula XXIII:
wherein
R 1 , R 2 , R 3 , R 4 , R 5 and R 6 are independently hydrogen, O-alkyl, O-haloalkyl, F, Cl, Br, I, haloalkyl, CN, —CH 2 CN, NH 2 , hydroxyl, —(CH 2 ) i NHCH 3 , —(CH 2 ) i NH 2 , —(CH 2 ) i N(CH 3 ) 2 , —OC(O)CF 3 , C 1 -C 5 linear or branched alkyl, alkylamino, aminoalkyl, —OCH 2 Ph, —NHCO-alkyl, COOH, —C(O)Ph, C(O)O-alkyl, C(O)H, —C(O)NH 2 or NO 2 , wherein R 4 , R 5 , and R 6 cannot all be hydrogen;
R 9 is hydrogen, linear or branched, substituted or unsubstituted alkyl, substituted or unsubstituted cycloalkyl, substituted or unsubstituted aryl, —CH 2 Ph, substituted benzyl, haloalkyl, aminoalkyl, —OCH 2 Ph, substituted or unsubstituted SO 2 -aryl, substituted or unsubstituted —(C═O)-aryl or OH;
R 12 is linear or branched, substituted or unsubstituted alkyl, substituted or unsubstituted cycloalkyl, —CH 2 Ph, substituted benzyl, haloalkyl, aminoalkyl, —OCH 2 Ph, substituted or unsubstituted SO 2 -aryl, substituted or unsubstituted —(C═O)-aryl or OH;
wherein substitutions are independently selected from the group of hydroxyl, an aliphatic straight- or branched-chain C 1 to C 10 hydrocarbon, alkoxy, haloalkoxy, aryloxy, nitro, cyano, alkyl-CN, halo, haloalkyl, dihaloalkyl, trihaloalkyl, COOH, C(O)Ph, C(O)-alkyl, C(O)O-alkyl, C(O)H, C(O)NH 2 , —OC(O)CF 3 , —OCH 2 Ph, amino, aminoalkyl, alkylamino, mesylamino, dialkylamino, arylamino, amido, NHC(O)-alkyl, urea, alkyl-urea, alkylamido, haloalkylamido, arylamido, aryl, and C 5 to C 7 cycloalkyl, arylalkyl, and combinations thereof;
X is NH, C 1 to C 5 hydrocarbon, O, or S;
Y is —C═S, —C═N—NH 2 , —C═N—OH, —CH—OH, —C═CH—CN, —C═N—CN, —C═C(CH 3 ) 2 , —C═N—OMe, —(C═O)—NH, —NH—(C═O), —(C═O)—O, —O—(C═O), —(CH 2 ) 1-5 —(C═O), (C═O)—(CH 2 ) 1-5 , —(SO 2 )—NH—, —NH—(SO 2 )—, SO 2 , SO or S;
i is an integer between 0-5;
n is an integer between 1-3; and
m is an integer between 1-3;
or its pharmaceutically acceptable salt.